Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Lisuride is a small molecule ergot derivative of the ergoline family, used primarily as an antiparkinsonian agent, for migraine prophylaxis, and to treat conditions associated with high prolactin levels such as hyperprolactinaemia and acromegaly. It acts mainly as an agonist at dopamine D2 receptors and several serotonin receptors (notably 5‑HT1A, 5‑HT2A/2C), with additional antagonist activity at dopamine D1 and histamine H1 receptors. Its dopaminergic activity underlies its use in Parkinson’s disease and prolactin suppression, while serotonergic effects contribute to migraine prevention. Unlike some other ergot derivatives, lisuride does not cause psychedelic effects due to its strong 5‑HT1A agonism counteracting 5‑HT2A-mediated hallucinogenic pathways[1][2][3][6]. It is not approved in the United States but is marketed in various countries under multiple brand names.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on lisuride.